stockportfolio.pro
Genmab A/S (GMAB)
Healthcare · Biotechnology · NasdaqGS
Genmab A/S revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.09B | $2.39B | $3.12B | $3.72B |
| Gross profit | $2.09B | $2.36B | $2.98B | $3.48B |
| Net income | $784.70M | $631.00M | $1.13B | $963.00M |
| Net margin | 37.6% | 26.4% | 36.3% | 25.9% |
Source: Genmab A/S SEC filings (10-K).
What growth is priced into GMAB stock?
At today's market cap of $15.32B, Genmab A/S is priced for free-cash-flow growth of about 2.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.13B from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of Genmab A/S financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GMAB in your portfolio →
Genmab A/S financial history by metric
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Genmab A/S — frequently asked questions
What is Genmab A/S's revenue?
Genmab A/S (GMAB) reported revenue of $3.72B for fiscal year 2025, up 19.2% from the prior year, according to its SEC filings.
Is Genmab A/S profitable?
Yes. GMAB earned net income of $963.00M in fiscal 2025, a net margin of 25.9%.
What is GMAB's P/E ratio?
Genmab A/S trades at a price-to-earnings ratio of about 19.1 based on the latest data in our nightly-refreshed cache.
How fast is Genmab A/S growing?
GMAB's revenue grew at roughly 21.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Genmab A/S have?
As of fiscal year 2025, GMAB carried roughly $5.27B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Genmab A/S's gross margin?
GMAB's gross margin was 93.6% in fiscal 2025 — gross profit of $3.48B on revenue of $3.72B.
What is Genmab A/S's market cap?
Genmab A/S (GMAB) has a market capitalization of about $15.32B, based on the latest data in our nightly-refreshed cache.
When does Genmab A/S's fiscal year end?
GMAB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into GMAB stock?
At today's market cap of $15.32B, Genmab A/S is priced for free-cash-flow growth of about 2.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.13B from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Genmab A/S's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.